Halogen-containing lithium ion eutectic and preparation method and application thereof

Through lithium-ion eutectic technology, lithium and proline are used to form eutectics with halogen-containing carboxylic acid compounds, which solves the problem of poor water solubility, improves bioavailability and expands its drug application range.

CN118619869BActive Publication Date: 2024-11-22FOSHAN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411102655.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-22
Estimated Expiration
2044-08-13

AI Technical Summary

Technical Problem

Halogen-containing carboxylic acid compounds have poor water solubility, which hinder their bioavailability and clinical application.

Method used

The halogen-containing carboxylic acid compound, lithium and proline with a molar ratio of 1:1:1 is used to form lithium ion co-crystals, and the co-crystals are prepared by heating and dissolving, adding poor solvents, slowly evaporating solvents, crystallization, filtration and drying. Crystals improve their water solubility.

Benefits of technology

It significantly improves the solubility of halogen-containing carboxylic acid compounds in eutectics, enhances bioavailability, and has a wide range of drug application prospects, including therapeutic effects of antibacterial, antiviral, anti-inflammatory and mental illnesses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118619869B_ABST
    Figure CN118619869B_ABST
Patent Text Reader

Abstract

The present invention relates to the field of medical technology, and in particular to a halogen-containing lithium ion eutectic, a preparation method and application thereof. The halogen-containing lithium ion eutectic comprises a halogen-containing carboxylic acid compound, lithium and proline in a molar ratio of 1:1:1. The halogen-containing lithium ion eutectic has good solubility in water and can effectively improve the bioavailability of the halogen-containing carboxylic acid compound in the eutectic. In addition, the halogen-containing lithium ion eutectic can also be used to prepare lithium salt drugs, and has broad medicinal value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a halogen-containing lithium ion eutectic and a preparation method and application thereof. Background Art

[0002] Pharmaceutical cocrystals refer to new crystals formed by the combination of active pharmaceutical ingredients (API) and cocrystal formers (CCF) in a fixed stoichiometric ratio through non-covalent interactions. They are a new type of solid form that has emerged in recent decades. Researchers have found that this technology can improve the physical and chemical properties of drugs without changing their molecular structure, so it has received increasing attention in the modification of APIs in recent years. Pharmaceutical cocrystals can be divided into molecular cocrystals (MCCs) and ionic cocrystals (ICCs). MCCs are composed of two components, one API and the other CCF. ICCs have at least three components: cations, anions and neutral molecules, at least one of which is biologically active. Compared with MCCs, ICCs have at least two components that can be changed, which greatly increases the diversity of drug design and selection. This diversity makes ICCs have a broader application prospect in the field of drug research and development.

[0003] Halogen-containing carboxylic acid compounds such as halogen-substituted salicylic acid derivatives have strong antibacterial, antiviral and anti-inflammatory properties, but they contain carboxyl and hydroxyl groups and are weakly acidic (pKa2-4), resulting in poor water solubility, which seriously hinders their bioavailability and clinical application.

[0004] It can be seen that the existing technology still needs to be improved and enhanced. Summary of the invention

[0005] In view of the above-mentioned deficiencies in the prior art, the object of the present invention is to provide a halogen-containing lithium ion eutectic and a preparation method and application thereof, aiming to improve the water solubility of halogen-containing carboxylic acid compounds.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] A first aspect of the present invention provides a halogen-containing lithium ion eutectic comprising a halogen-containing carboxylic acid compound, lithium and proline in a molar ratio of 1:1:1.

[0008] The halogen-containing lithium ion eutectic, wherein the halogen-containing carboxylic acid compound contains at least one of fluorine, chlorine, bromine or iodine.

[0009] The halogen-containing lithium ion eutectic, wherein the halogen-containing carboxylic acid compound includes at least one of 2-trifluoromethoxybenzoic acid, 4-trifluoromethylsalicylic acid, 5-fluorosalicylic acid, 5-chlorosalicylic acid, 5-bromosalicylic acid, and 5-iodosalicylic acid.

[0010] The halogen-containing lithium ion eutectic, wherein when the halogen-containing lithium ion eutectic is a 2-trifluoromethoxybenzoic acid-lithium-(L-)proline eutectic, the powder X-ray diffraction pattern of the 2-trifluoromethoxybenzoic acid-lithium-(L-)proline eutectic includes the following characteristic peaks: 6.47°, 11.15°, 16.31°, 12.71°, 18.98°, 19.46°, 20.15°, 26.33°, 31.76°;

[0011] When the halogen-containing lithium ion eutectic is 4-trifluoromethylsalicylic acid-lithium-(L-)proline eutectic, the powder X-ray diffraction pattern of the 4-trifluoromethylsalicylic acid-lithium-(L-)proline eutectic includes the following characteristic peaks: 10.73°, 17.30°, 17.87°, 18.50°, 26.03°, 26.42°;

[0012] When the halogen-containing lithium ion eutectic is a 5-fluorosalicylic acid-lithium-(L-)proline eutectic, the powder X-ray diffraction pattern of the 5-fluorosalicylic acid-lithium-(L-)proline eutectic includes the following characteristic peaks: 7.58°, 11.42°, 19.31°, 22.79°, 24.08°, and 28.34°;

[0013] When the halogen-containing lithium ion eutectic is a 5-chlorosalicylic acid-lithium-(L-)proline eutectic, the powder X-ray diffraction pattern of the 5-chlorosalicylic acid-lithium-(L-)proline eutectic includes the following characteristic peaks: 11.24°, 19.07°, 21.89°, 22.37°, 25.34°, and 26.48°;

[0014] When the halogen-containing lithium ion eutectic is a 5-bromosalicylic acid-lithium-(L-)proline eutectic, the powder X-ray diffraction pattern of the 5-bromosalicylic acid-lithium-(L-)proline eutectic includes the following characteristic peaks: 7.25°, 14.24°, 16.76°, 18.83°, 21.77°, 23.33°, 26.24°;

[0015] When the halogen-containing lithium ion eutectic is a 5-iodosalicylic acid-lithium-(L-)proline eutectic, the powder X-ray diffraction pattern of the 5-iodosalicylic acid-lithium-(L-)proline eutectic includes the following characteristic peaks: 6.95°, 13.70°, 16.10°, 19.40°, 22.13°, and 24.20°.

[0016] A second aspect of the present invention provides a method for preparing a halogen-containing lithium ion eutectic, which is used to prepare the halogen-containing lithium ion eutectic as described above, comprising the following steps: heating and dissolving lithium hydroxide, a halogen-containing carboxylic acid compound, and proline in a good solvent, adding a poor solvent, slowly volatilizing the solvent, crystallizing, filtering and drying to obtain the halogen-containing lithium ion eutectic.

[0017] Preferably, the molar ratio of the lithium hydroxide, the halogen-containing carboxylic acid compound and proline is (1-2): (1-2): (1-2).

[0018] Preferably, the good solvent is one or more of water, methanol, ethanol, acetonitrile, dimethyl sulfoxide, isopropanol, 3-methyl-1-butanol, acetone, methyl ethyl ketone, methyl isobutyl ketone, 2-methyl-1-propanol, 1-pentanol, 1-propanol, 2-propanol, and chloroform.

[0019] Preferably, the poor solvent is one or more of ethyl acetate, methyl formate, ethyl formate, methyl acetate, butyl acetate, ethyl formate, isobutyl acetate, isopropyl acetate, methyl acetate, toluene, ethyl ether, pentane, and tetrahydrofuran.

[0020] The present invention also provides the use of the halogen-containing lithium ion eutectic as described above in the preparation of lithium salt drugs.

[0021] The present invention also provides the use of the halogen-containing lithium ion eutectic as described above in the preparation of drugs for treating neurological diseases or mental diseases.

[0022] The present invention also provides the use of the halogen-containing lithium ion eutectic as described above in the preparation of antibacterial, antiviral and anti-inflammatory drugs.

[0023] The present invention also provides the use of the 4-trifluoromethylsalicylic acid-lithium-(L-)proline cocrystal in preparing drugs for treating cancer or cardiac hypertrophy.

[0024] Beneficial effects: The present invention provides a halogen-containing lithium ion eutectic, which comprises a halogen-containing carboxylic acid compound, lithium and proline in a molar ratio of 1:1:1. The eutectic has good water solubility, greatly increases the solubility of the halogen-containing carboxylic acid compound in the eutectic, and improves its bioavailability. In addition, the proline in the eutectic can improve the immune function of the user. The eutectic of the present invention is also a lithium salt, which has a good therapeutic effect on mental illness in clinical practice. Therefore, the eutectic of the present invention has good clinical application prospects.

[0025] The present invention also provides a method for preparing a halogen-containing lithium ion eutectic. The preparation method uses lithium hydroxide, a halogen-containing carboxylic acid compound and proline to prepare the halogen-containing lithium ion eutectic. Through process control, the obtained eutectic can be in the best crystal state. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 This is the crystal structure diagram of the eutectic of Example 1.

[0027] Figure 2 This is the crystal structure diagram of the eutectic of Example 2.

[0028] Figure 3 This is the crystal structure diagram of the eutectic of Example 3.

[0029] Figure 4 This is the crystal structure diagram of the eutectic of Example 4.

[0030] Figure 5 This is the crystal structure diagram of the eutectic of Example 5.

[0031] Figure 6 This is the crystal structure diagram of the eutectic of Example 6.

[0032] Figure 7 This is the powder X-ray diffraction pattern (PXRD) of the co-crystal of Example 1.

[0033] Figure 8 This is the powder X-ray diffraction pattern (PXRD) of the co-crystal of Example 2.

[0034] Fig. 9 This is the powder X-ray diffraction pattern (PXRD) of the co-crystal of Example 3.

[0035] Fig.10 This is the powder X-ray diffraction pattern (PXRD) of the co-crystal of Example 4.

[0036] Fig.11 This is the powder X-ray diffraction pattern (PXRD) of the co-crystal of Example 5.

[0037] Fig.12 This is the powder X-ray diffraction pattern (PXRD) of the co-crystal of Example 6.

[0038] Fig.13 This is the differential scanning calorimetry (DSC) diagram of the co-crystal of Example 1.

[0039] Fig.14 This is the differential scanning calorimetry (DSC) diagram of the co-crystal of Example 2.

[0040] Fig.15 This is the differential scanning calorimetry (DSC) diagram of the co-crystal of Example 3.

[0041] Fig.16 This is the differential scanning calorimetry (DSC) diagram of the co-crystal of Example 4.

[0042] Fig.17 This is the differential scanning calorimetry (DSC) diagram of the co-crystal of Example 5.

[0043] Fig.18 This is the differential scanning calorimetry (DSC) diagram of the co-crystal of Example 6.

[0044] Fig.19 This is the solubility diagram of halogen-substituted salicylic acid raw materials in water.

[0045] Fig. 20 This is the solubility diagram of halogen-substituted salicylic acid-lithium-(L-)proline eutectic in water. DETAILED DESCRIPTION

[0046] The present invention provides a halogen-containing lithium ion eutectic and a preparation method and application thereof. In order to make the purpose, technical solution and effect of the present invention clearer and more specific, the present invention is further described in detail with reference to the accompanying drawings and examples. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0047] The first aspect of the present invention provides a halogen-containing lithium ion eutectic, comprising a halogen-containing carboxylic acid compound, lithium and proline in a molar ratio of 1:1:1. In the present invention, after the halogen-containing carboxylic acid compound, lithium and proline are eutectic, the solubility of the halogen-substituted halogen-containing carboxylic acid compound can be greatly increased, and its bioavailability can be improved.

[0048] The halogen-containing lithium ion eutectic provided by the present invention has broad prospects for drug application. When the halogen-containing carboxylic acid compound is halogen-containing salicylic acid and its derivatives, the halogen-containing lithium ion eutectic provided by the present invention can be used to prepare antibacterial, antiviral and anti-inflammatory drugs. Clinically, salicylic acid and its derivatives belong to non-steroidal anti-inflammatory drugs, and have a wide range of pharmacological effects such as antipyretic, analgesic and anti-inflammatory. Halogen (fluorine, chlorine, bromine and iodine) substitution plays an important role in drug research and development. Due to the higher electronegativity, the halogen substituent can increase the chemical stability of the aromatic ring and enhance the biological activity. For example, halogen-substituted salicylic acid derivatives have stronger antibacterial, antiviral and anti-inflammatory properties.

[0049] In addition, the halogen-containing lithium ion eutectic of the present invention contains lithium, and therefore, can also be used as a lithium salt drug. In psychiatry, lithium salt drugs have been used to treat mania and prevent depression since the mid-20th century. Recent studies have also shown that lithium salts have significant effects in treating Alzheimer's disease, treating viral infections, reducing suicide, etc.

[0050] The proline contained in halogen-containing lithium ion eutectics helps promote muscle growth, improve immune function and promote energy metabolism, among which L-proline is the most common and most biologically active form.

[0051] Specifically, the halogen-containing carboxylic acid compound contains at least one of fluorine, chlorine, bromine or iodine.

[0052] Preferably, the halogen-containing carboxylic acid compound includes at least one of 2-trifluoromethoxybenzoic acid, 4-trifluoromethyl salicylic acid, 5-fluorosalicylic acid, 5-chlorosalicylic acid, 5-bromosalicylic acid, and 5-iodosalicylic acid. Among them, studies have shown that 4-trifluoromethylsalicylic acid also has good COX enzyme inhibitory activity, can effectively inhibit the expression of inflammatory proteins, inhibit the transcription of NF-kB in astroglioma cells, and cardiac hypertrophy, etc. After 4-trifluoromethylsalicylic acid is used to prepare 4-trifluoromethylsalicylic acid-lithium-(L-)proline cocrystal, the effectiveness is expected to be further improved.

[0053] The second aspect of the present invention provides a method for preparing a halogen-containing lithium ion eutectic, which is used to prepare the halogen-containing lithium ion eutectic as described above, comprising the following steps: heating and dissolving lithium hydroxide, a halogen-containing carboxylic acid compound, and proline in a good solvent (positive solvent), adding a poor solvent (anti-solvent), slowly volatilizing the solvent, crystallizing, filtering and drying, and obtaining the halogen-containing lithium ion eutectic. The present invention adopts anti-solvent crystallization, dissolving the product to be purified with a good solvent, and then adding a poor solvent thereto to precipitate the product. The advantage is that the solubility of the product to be crystallized in the solvent is reduced by adding a poor solvent to achieve crystallization purification.

[0054] Preferably, the molar ratio of the lithium hydroxide, the halogen-containing carboxylic acid compound, and the proline is (1-2): (1-2): (1-2). Within this dosage range, the waste of raw materials can be reduced.

[0055] Preferably, the good solvent is one or more of water, methanol, ethanol, acetonitrile, dimethyl sulfoxide, isopropanol, 3-methyl-1-butanol, acetone, methyl ethyl ketone, methyl isobutyl ketone, 2-methyl-1-propanol, 1-pentanol, 1-propanol, 2-propanol, and chloroform.

[0056] Preferably, the poor solvent is one or more of ethyl acetate, methyl formate, ethyl formate, methyl acetate, butyl acetate, ethyl formate, isobutyl acetate, isopropyl acetate, methyl acetate, toluene, ethyl ether, pentane, and tetrahydrofuran.

[0057] Preferably, the temperature of the volatile solvent is 25-80°C.

[0058] Preferably, the heating and dissolving time is 15 to 90 minutes.

[0059] Preferably, the heating and dissolving time is at a temperature of 60 to 90° C. When different components are used to prepare halogen-containing lithium ion eutectics, the optimal heating and dissolving temperatures are different. At different heating and dissolving temperatures, the states of the eutectic during crystallization are different.

[0060] Example 1

[0061] A lithium ion eutectic of 2-trifluoromethoxybenzoic acid, wherein the preparation method comprises the following steps:

[0062] Lithium hydroxide, 2-trifluoromethoxybenzoic acid and L-proline in a molar ratio of 1:1:1 were placed in a round-bottom flask, 80% methanol was added thereto, and the round-bottom flask was placed in a magnetic heating stirrer, heated and stirred at 65°C for 60 minutes under reflux;

[0063] After the reaction is completed, an appropriate amount of ethyl acetate is added, and the solvent is slowly evaporated at room temperature to obtain colorless and transparent block crystals, which are 2-trifluoromethoxybenzoic acid-lithium-(L-)proline cocrystals.

[0064] Example 2

[0065] A lithium ion eutectic of 4-trifluoromethylsalicylic acid is prepared by the following method:

[0066] Lithium hydroxide, 4-trifluoromethylsalicylic acid and L-proline in a molar ratio of 1:1:1 were placed in a round-bottom flask, 10% ethanol was added thereto, and the mixture was placed in a magnetic heating stirrer, heated and stirred at 90°C for 60 minutes under reflux;

[0067] After the reaction is completed, an appropriate amount of ethyl acetate is added, and the solvent is slowly evaporated at room temperature to obtain colorless and transparent strip crystals, which are 4-trifluoromethylsalicylic acid-lithium-(L-)proline cocrystals.

[0068] Example 3

[0069] A lithium ion eutectic of 5-fluorosalicylic acid is prepared by the following method:

[0070] Lithium hydroxide, 5-fluorosalicylic acid and L-proline in a molar ratio of 1:1:1 were placed in a round-bottom flask, 80% ethanol was added thereto, and the mixture was placed in a magnetic heating stirrer, heated and stirred at 65°C for 60 minutes under reflux;

[0071] After the reaction was completed, an appropriate amount of ethyl acetate was added, and the solvent was slowly evaporated at room temperature to obtain colorless and transparent needle-shaped crystals, which were 5-fluorosalicylic acid-lithium-(L-)proline cocrystals.

[0072] Example 4

[0073] A lithium ion eutectic of 5-chlorosalicylic acid is prepared by the following method:

[0074] Lithium hydroxide, 5-chlorosalicylic acid and L-proline in a molar ratio of 1:1:1 were placed in a round-bottom flask, distilled water was added thereto, and the flask was placed in a magnetic heating stirrer, heated and stirred at 90°C for 60 minutes under reflux;

[0075] After the reaction is completed, an appropriate amount of ethyl acetate is added, and the solvent is slowly evaporated at room temperature to obtain colorless and transparent strip crystals, which are 5-chlorosalicylic acid-lithium-(L-)proline cocrystals.

[0076] Example 5

[0077] A lithium ion eutectic of 5-bromosalicylic acid is prepared by the following method:

[0078] Lithium hydroxide, 5-bromosalicylic acid and L-proline in a molar ratio of 1:1:1 were placed in a round-bottom flask, 70% methanol was added thereto, and the mixture was placed in a magnetic heating stirrer, heated and stirred at 65°C for 60 minutes under reflux;

[0079] After the reaction is completed, an appropriate amount of ethyl acetate is added, and the solvent is slowly evaporated at room temperature to obtain colorless and transparent strip crystals, which are 5-bromosalicylic acid-lithium-(L-)proline cocrystals.

[0080] Example 6

[0081] A lithium ion eutectic of 5-iodosalicylic acid is prepared by the following method:

[0082] A certain amount of lithium hydroxide, 5-iodosalicylic acid and L-proline were placed in a round-bottom flask, 70% methanol was added thereto, and the mixture was placed in a magnetic heating stirrer, heated and stirred at 75°C for 60 minutes under reflux;

[0083] After the reaction is completed, an appropriate amount of ethyl acetate is added, and the solvent is slowly evaporated at room temperature to obtain colorless and transparent strip crystals, which are 5-iodosalicylic acid-lithium-(L-)proline cocrystals.

[0084] The halogen-containing lithium ion eutectic prepared in each embodiment of the present invention was characterized and its performance was measured. The specific method is as follows:

[0085] 1. Single crystal X-ray diffractometer D8 QUEST ECO was used for detection, the test temperature was 293 (2) K, CuKa radiation was used, crystal data was collected in ω scanning mode and Lp correction was performed. The structure was analyzed by direct method, and all non-hydrogen atoms were found by difference Fourier method. All hydrogen atoms on carbon and nitrogen were obtained by theoretical hydrogenation. The structure was refined by least square method. The crystal structure of the cocrystal of Example 1-6 is shown in Figures 1 to 6 shown.

[0086] 2. At ambient temperature, the PXRD pattern was measured by an X-ray powder diffractometer. The measurement conditions were as follows: scanning range 5°-50°, scanning rate 8° / min, emission target Cu Kα, voltage and current 40kV and 100mA respectively. The X-ray diffraction pattern of the obtained cocrystal was compared with the X-ray diffraction patterns of the two raw materials (halogen-containing carboxylic acid compound and proline). The results are as follows: Figures 7 to 12 shown.

[0087] The results show:

[0088] The 2-trifluoromethoxybenzoic acid-lithium-(L-)proline cocrystal has characteristic peaks at 6.47°, 11.15°, 16.31°, 12.71°, 18.98°, 19.46°, 20.15°, 26.33°, and 31.76°.

[0089] 4-Trifluoromethylsalicylate-lithium-(L-)proline has characteristic peaks at 10.73°, 17.30°, 17.87°, 18.50°, 26.03°, and 26.42°.

[0090] 5-Fluorosalicylate-lithium-(L-)proline has characteristic peaks at 7.58°, 11.42°, 19.31°, 22.79°, 24.08°, and 28.34°.

[0091] The 5-chlorosalicylic acid-lithium-(L-)proline cocrystal has characteristic peaks at 11.24°, 19.07°, 21.89°, 22.37°, 25.34°, and 26.48°.

[0092] 5-Bromosalicylate-lithium-(L-)proline has characteristic peaks at 7.25°, 14.24°, 16.76°, 18.83°, 21.77°, 23.33°, and 26.24°.

[0093] The 5-iodosalicylate-lithium-(L-)proline cocrystal has characteristic peaks at 6.95°, 13.70°, 16.10°, 19.40°, 22.13°, and 24.20°.

[0094] 3. The eutectics obtained in Examples 1 to 6 were subjected to DSC analysis using a differential scanning calorimeter 60 Plus at a test temperature of 30-300° C., a heating rate of 10 K / min, and a protective nitrogen atmosphere of 20.0 mL / min.

[0095] The results are as follows Figures 13 to 18 As shown, the results indicate that new endothermic peaks or diffraction peaks that are significantly different from those of the monomers are formed in each co-crystal, confirming the formation of a new phase in the co-crystal.

[0096] The solubility in water of the raw materials and the prepared co-crystals used in Examples 1 to 6 was measured by high performance liquid chromatography.

[0097] The results are as follows Figures 19 to 20 As shown, the results indicate that the preparation of the eutectic of the present invention can greatly improve the solubility (mg / ml) of the halogen-containing carboxylic acid compound in water.

[0098] The solubility of the raw material 2-trifluoromethoxybenzoic acid in water is 2.74 mg / ml, while the solubility of this raw material in water in the 2-trifluoromethoxybenzoic acid-lithium-(L-)proline eutectic is 472.94 mg / ml.

[0099] The solubility of the raw material 4-trifluoromethylsalicylic acid in water is 1.50 mg / ml, while the solubility of this raw material in water in the 4-trifluoromethylsalicylic acid-lithium-(L-)proline cocrystal is 181.52 mg / ml.

[0100] The solubility of the raw material 5-fluorosalicylic acid in water is 2.34 mg / ml, while the solubility of this raw material in water in the 5-fluorosalicylic acid-lithium-(L-)proline cocrystal is 158.92 mg / ml.

[0101] The solubility of the raw material 5-chlorosalicylic acid in water is 0.83 mg / ml, while the solubility of this raw material in water in the 5-chlorosalicylic acid-lithium-(L-)proline cocrystal is 95.43 mg / ml.

[0102] The solubility of the raw material 5-bromosalicylic acid in water is 1.17 mg / ml, while the solubility of this raw material in water in the 5-bromosalicylic acid-lithium-(L-)proline cocrystal is 179.60 mg / ml.

[0103] The solubility of the raw material 5-iodosalicylic acid in water is 0.49 mg / ml, while the solubility of this raw material in water in the 5-iodosalicylic acid-lithium-(L-)proline cocrystal is 366.11 mg / ml.

[0104] Before the eutectic treatment, among the raw materials 5-fluorosalicylic acid, 5-chlorosalicylic acid, 5-bromosalicylic acid and 5-iodosalicylic acid, 5-iodosalicylic acid has the lowest solubility in water. However, the solubility of 5-iodosalicylic acid-lithium-(L-)proline eutectic prepared from 5-iodosalicylic acid in water is the highest among the four eutectics.

[0105] It is understandable that those skilled in the art can make equivalent substitutions or changes based on the technical solution and inventive concept of the present invention, and all these changes or substitutions should fall within the protection scope of the claims attached to the present invention.

Claims

1. A halogen-containing lithium ion eutectic, characterized in that: The invention comprises a halogen-containing carboxylic acid compound, lithium and proline in a molar ratio of 1:1:1; the halogen-containing carboxylic acid compound contains at least one of fluorine, bromine or iodine; the halogen-containing carboxylic acid compound comprises at least one of 2-trifluoromethoxybenzoic acid, 4-trifluoromethylsalicylic acid, 5-fluorosalicylic acid, 5-bromosalicylic acid and 5-iodosalicylic acid; When the halogen-containing lithium ion eutectic is a 2-trifluoromethoxybenzoic acid-lithium-L-proline eutectic, the powder X-ray diffraction pattern of the 2-trifluoromethoxybenzoic acid-lithium-L-proline eutectic includes the following characteristic peaks: 6.47°, 11.15°, 16.31°, 12.71°, 18.98°, 19.46°, 20.15°, 26.33°, and 31.76°; When the halogen-containing lithium ion eutectic is 4-trifluoromethylsalicylic acid-lithium-L-proline eutectic, the powder X-ray diffraction pattern of the 4-trifluoromethylsalicylic acid-lithium-L-proline eutectic includes the following characteristic peaks: 10.73°, 17.30°, 17.87°, 18.50°, 26.03°, 26.42°; When the halogen-containing lithium ion eutectic is a 5-fluorosalicylic acid-lithium-L-proline eutectic, the powder X-ray diffraction pattern of the 5-fluorosalicylic acid-lithium-L-proline eutectic includes the following characteristic peaks: 7.58°, 11.42°, 19.31°, 22.79°, 24.08°, and 28.34°; When the halogen-containing lithium ion eutectic is a 5-bromosalicylic acid-lithium-L-proline eutectic, the powder X-ray diffraction pattern of the 5-bromosalicylic acid-lithium-L-proline eutectic includes the following characteristic peaks: 7.25°, 14.24°, 16.76°, 18.83°, 21.77°, 23.33°, and 26.24°; When the halogen-containing lithium ion eutectic is a 5-iodosalicylic acid-lithium-L-proline eutectic, the powder X-ray diffraction pattern of the 5-iodosalicylic acid-lithium-L-proline eutectic includes the following characteristic peaks: 6.95°, 13.70°, 16.10°, 19.40°, 22.13°, and 24.20°.

2. A method for preparing a halogen-containing lithium ion eutectic, characterized in that: The method for preparing the halogen-containing lithium ion eutectic as claimed in claim 1 comprises the following steps: heating and dissolving lithium hydroxide, a halogen-containing carboxylic acid compound and proline in a good solvent, adding a poor solvent, slowly volatilizing the solvent, crystallizing, filtering and drying to obtain the halogen-containing lithium ion eutectic.

3. The method for preparing a halogen-containing lithium ion eutectic according to claim 2, characterized in that: The molar ratio of the lithium hydroxide, the halogen-containing carboxylic acid compound and the proline is (1-2): (1-2): (1-2); The good solvent is one or more of water, methanol, ethanol, acetonitrile, dimethyl sulfoxide, isopropanol, 3-methyl-1-butanol, acetone, methyl ethyl ketone, methyl isobutyl ketone, 2-methyl-1-propanol, 1-pentanol, 1-propanol, 2-propanol, and chloroform; The poor solvent is one or more of ethyl acetate, methyl formate, ethyl formate, methyl acetate, butyl acetate, isobutyl acetate, isopropyl acetate, toluene, ethyl ether, pentane and tetrahydrofuran.

4. Use of the halogen-containing lithium ion eutectic according to claim 1 in the preparation of lithium salt drugs.